NCT05307705: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

NCT05307705
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have solid tumor with the presence of a PIK3CA H1047R mutation
Exclusions: Patients with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement; Patients with prior exposure to PI3K/AKT/mTOR inhibitor(s) – see trial for details
https://ClinicalTrials.gov/show/NCT05307705

Comments are closed.

Up ↑